XENIOS, a German firm, won the European CE Mark of approval to introduce the i-cor Synchronized Cardiac Assist System. The i-cor provides beat-to-beat blood flow augmentation, pushing with the heart’s own rhythm, the first system to do so. Almost all previously used heart assist devices provide continuous flow pressure, but the i-cor monitors the patient’s ECG and activates the pumping action along with that signal. It’s intended for use in patients suffering from cardiogenic shock as well as during high-risk interventions.
The technology is aimed at optimizing the efficiency of the cardiac assistance, improving organ perfusion, and reducing stress on the patients. Additionally, due to a reduced blood flow administered, the system uses a smaller endovascular cannula than before.
From XENIOS:
XENIOS, a German firm, won the European CE Mark of approval to introduce the i-cor Synchronized Cardiac Assist System. The i-cor provides beat-to-beat blood flow augmentation, pushing with the heart’s own rhythm, the first system to do so. Almost all previously used heart assist devices provide continuous flow pressure, but the i-cor monitors the patient’s ECG and activates the pumping action along with that signal. It’s intended for use in patients suffering from cardiogenic shock as well as during high-risk interventions.The technology is aimed at optimizing the efficiency of the cardiac assistance, improving organ perfusion, and reducing stress on the patients. Additionally, due to a reduced blood flow administered, the system uses a smaller endovascular cannula than before.From XENIOS:
การแปล กรุณารอสักครู่..
